logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
L

Laura M. Spring

mass general brig ham cancer institute
H指数:36
被引数:6,832

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability

转移性化生性三阴性乳腺癌对沙库巴曲珠单抗的应答及生物标志物靶向性

Breast Cancer Research and Treatment
IF3
2026-09-300
PRE
Shivahamy Maheswaran; Aylin S. Dedeoglu; Andrzej Niemierko; Rachel O. Abelman; Rachel Jimenez; Olivia Rieur; Jennifer Hutchinson; Neelima Vidula; Laura M. Spring; Leif W. Ellisen; Steven J. Isakoff; Seth A. Wander; Aditya Bardia; Arielle J. Medford
Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

来自12,827例转移性乳腺癌患者循环DNA中可操作的遗传景观和动态

Nature Communications
IF15.7
2026-09-220
OAAI
Ignaty Leshchiner; Arielle J. Medford; Justin Cha; Lesli A. Kiedrowski; Andrzej Niemierko; Jennifer C. Keenan; Charles S. Dai; Laura M. Spring; Beverly Moy; Seth A. Wander; Neelima Vidula; Steven J. Isakoff; Dejan Juric; Mendy Miller; Andrew A. Davis; Lorenzo Gerratana; Ami Shah; Ben H. Park; Adam Brufsky; Joyce O’Shaughnessy; Rebecca J. Nagy; Leif W. Ellisen; Massimo Cristofanilli; Aditya Bardia; Gad Getz
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial

伊帕西替布联合内分泌疗法和CDK4/6抑制剂在HR+/HER2–转移性乳腺癌中的安全性和抗肿瘤活性（TAKTIC）：一项单中心、开放标签、1b期临床试验

The Lancet Oncology
IF0
2026-04-270
PRE
Seth A Wander; Maxwell R Lloyd; Jennifer C Keenan; Elizabeth C Scott; Andrzej Niemierko; Laura M Spring; Geoffrey G Fell; Jennifer Shin; Steven J Isakoff; Beverly Moy; Lianne Ryan; Sarah Padden; Elizabeth Fisher; Amber Newton; Karleen R Habin; Elene T Viscosi-Spieler; Lauren Scarpetti; Andreas Varkaris; Leif W Ellisen; Taronish Dubash
Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States

曲拉留单抗 govitecan 的有效性及在美国真实世界环境中治疗转移性三阴性乳腺癌患者的中性粒细胞减少症管理

ESMO Open
IF8.3
2025-06-010
OA
R. Nanda; C. Yam; L. Spring; M.A. Bhave; I. Ntalla; T. Valdez; B. Stwalley; C. Liang; W.-H. Wu; N. Sjekloca; N. Sadetsky; C. Lai; K. Kalinsky
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)
NPJ BREAST CANCER
IF7.6
2025-01-070
OA
Spring, Laura M.; Scarpetti, Lauren; Medford, Arielle J.; Niemierko, Andrzej; Comander, Amy; Mulvey, Therese; Schnipper, Lowell; Isakoff, Steven J.; Moy, Beverly; Wander, Seth A.; Shin, Jennifer; Ephrem, Zanta; Laposta, Anneke R.; Denault, Elyssa; Abraham, Elizabeth; Calistro, Gayle; Kalashnikova, Ekaterina; Rodriguez, Angel; Liu, Minetta C.; Aleshin, Alexey; Peppercorn, Jeffrey; Ellisen, Leif W.; Bardia, Aditya
Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2-early breast cancer (EBC) from US electronic health records (EHR)

来自美国电子健康记录（EHR）的关于淋巴结阴性（N0）和淋巴结阳性人表皮生长因子受体2阴性（HR+/HER2-）早期乳腺癌（EBC）患者复发风险（ROR）的真实世界证据

ANNALS OF ONCOLOGY
IF65.4
2024-09-012
PRE
Jhaveri, K.; Pegram, M.; Neven, P.; Curigliano, G.; Spring, L. M.; Gligorov, J.; Schlam, I.; Harbeck, N.; Juric, D.; Lim, E.; Wang, S.; Owusu, H.; Akdere, M.; Ye, F.; Kim, J.; Cardoso, F.
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States

sacituzumab govitecan在美国转移性三阴性乳腺癌二线和后线治疗中的实际使用模式，有效性和耐受性

BREAST CANCER RESEARCH AND TREATMENT
IF3
2024-06-213
OAAI
Kalinsky, Kevin; Spring, Laura; Yam, Clinton; Bhave, Manali Ajay; Ntalla, Ioanna; Lai, Catherine; Sjekloca, Nikoleta; Stwalley, Brian; Stokes, Michael; Taylor, Aliki; Nanda, Rita
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

抗体药物偶联物Sacituzumab Govitecan可在乳腺癌患者中实现序贯TOP1/PARP抑制剂治疗策略

CLINICAL CANCER RESEARCH
IF10.2
2024-05-066
OAAI
Bardia, Aditya; Sun, Sheng; Thimmiah, Nayana; Coates, James T.; Wu, Bogang; Abelman, Rachel O.; Spring, Laura; Moy, Beverly; Ryan, Phoebe; Melkonyan, Mark N.; Partridge, Ann; Juric, Dejan; Peppercorn, Jeffrey; Parsons, Heather; Wander, Seth A.; Attaya, Victoria; Lormil, Brenda; Shellock, Maria; Nagayama, Aiko; Bossuyt, Veerle; Isakoff, Steven J.; Tolaney, Sara M.; Ellisen, Leif W.
Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Varkaris, Andreas; de la Cruz, Ferran Fece; Martin, Elizabeth; Nordern, Bryanna; Chevalier, Nicholas; Leshchiner, Ignaty; Stavridi, Anastasia; Kim, Janice; Papatheodoridi, Alkistis; Gunaydin, Hakan; Danysh, Brian; Parida, Laxmi; Sanidas, Ioannis; Ji, Yongli; Lau, Kayao; Wulf, Gerburg; Bardia, Aditya; Spring, Laura; Isakoff, Steven; Lennerz, Jochen; Pierce, Levi; Pazolli, Ermira; Getz, Gad; Corcoran, Ryan; Juric, Dejan
Neoadjuvant HER2-targeted Therapy plus /Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial
CANCER RESEARCH
IF16.6
2024-05-020
PRE
McArthur, Heather; Leal, Jorge Henrique Santos; Chan, Isaac; Unni, Nisha; Shiao, Stephen; Gruber, Joshua; Syed, Samira; Peswani, Namrata; Sadeghi, Navid; Delgado, Glenda; Klemow, Dawn; Basho, Reva; Carter, Meredith; Badran, Mai; Qureshi, Nasir; Curtin, Jessica; Weese, Joshua; Rice, Stephanie; Phillips, Michelle; Chan, David; Hool, Hugo; Park, Dorothy; El-Masry, Mary; McAndrew, Philomena; Sikaria, Swati; Spring, Laura; Bardia, Aditya; Tighiouart, Mourad; Dadmanesh, Farnaz; Giuliano, Armando; Sanchez, Katherine; Page, David
Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Metzger, Otto; Kim, Se Eun; Tayob, Nabihah; Viale, Giuseppe; Yardley, Denise; Prat, Aleix; Abramson, Vandana; Spring, Laura; Waks, Adrienne; Wrabel, Eileen; Demeo, Michelle; Bardia, Aditya; Dell'Orto, Patrizia; Russo, Leila; King, Tari; Michor, Franziska; Winer, Eric; Polyak, Kornelia; Tolaney, Sara; Krop, Ian

研究方向

暂未获取到该数据
A
Aditya Bardia
H 指数:86论文数:1,148被引数:3.8万
S
Steven J. Isakoff
H 指数:60论文数:449被引数:2.6万
L
Leif W. Ellisen
H 指数:66论文数:464被引数:2.4万
B
Beverly Moy
H 指数:57论文数:429被引数:1.3万
D
Dejan Juric
H 指数:59论文数:732被引数:2.0万
S
Seth A. Wander
H 指数:35论文数:342被引数:5,366
A
Arielle J. Medford
H 指数:13论文数:146被引数:849
A
Andrzej Niemierko
H 指数:69论文数:483被引数:1.7万
N
Neelima Vidula
H 指数:22论文数:171被引数:1,353
R
Rachel O. Abelman
H 指数:9论文数:69被引数:446